Meet with… Johnson & Johnson California Innovation Center
Meet with… Johnson & Johnson California Innovation Center
Janssen Research & Development LLC , 3210 Merryfield Row , San Diego , CA 92121
May 02, 2013 from 12:30 PM to 14:30 PM (PDT)
$10 - $35
You've heard about the new Johnson & Johnson Innovation Centers and now is your chance to meet the team charged with a new kind of partnering program! Join us to be one of the first to hear from the Johnson & Johnson California Innovation Center in person and don’t miss the opportunity to apply for a one-on-one meeting!
10:30am | Registration & Networking
11:00am | Presentation & Q&A
11:45pm | Lunch & Networking
12:30pm | Optional Tours of Janssen Labs
12:30-3:30pm | One-on-one Meetings*
*Companies must apply ahead of time and be approved for a one-on-one meeting. The application period ends April 19th. APPLY HERE
The Johnson & Johnson California Innovation Center, focuses on identifying early-stage (pre-clinical proof-of-concept) innovation at academic institutions, start-up biotech companies and venture capital firms, and provides integrated capabilities to scout, evaluate, fund and onboard new science. The California innovation center is one of four Johnson & Johnson innovation centers with the goal to advance transformative healthcare solutions that deliver value and improve people’s lives around the world. Each center has broad deal-making capabilities, with flexibility to adapt deal structures, which enables innovators looking for partnerships access to a broad range of expertise and resources. Co-located in the Johnson & Johnson California Innovation Center is the Johnson & Johnson Development Corporation (JJDC) that provides venture capital for investment in external opportunities aligned with business strategies of The Johnson & Johnson Family of Companies. Since its inception in 1973, JJDC has been among the top-tier health care venture capital companies investing in and developing new businesses that create leading technologies, products, and services.
Members from the Johnson & Johnson California Innovation Center and JJDC team will screen applicants and be in attendance on May 2nd to present on how to partner with Johnson & Johnson. Leaders from all areas of the life science industry are encouraged to apply today!
About Johnson & Johnson California Innovation Center
The goal of the Johnson & Johnson California Innovation Center (JJIC) is to advance transformative healthcare solutions that deliver value and improve people’s lives around the world. They accomplish this by catalyzing new science and technology through collaboration and exchange of ideas. Their business development team is co-located at the facility of the Johnson & Johnson Family of Companies, and is responsible for all late-stage (post clinical proof-of-concept) opportunities. Business Development remains responsible for all collaborations with established pharmaceutical companies, mid-size and large biotech companies, all merger and acquisition (M&A) activities, and the divestiture of products and franchises.
Presentation & Lunch Only
$25 | General Public
Includes presentation, Q&A, lunch and optional tour of Janssen Labs
*No onsite registration
Presentation Lunch & One-on-One Meeting
It is free to apply, but upon acceptance the following fees will apply:
$75 | One Member of Your Team
$125 | Two Members of Your Team
$150 | Three Members of Your Team
Includes presentation, Q&A, lunch,optional tour of Janssen Labs and one-on-one meeting. Companies must have applied for a one-on-one meeting ahead of time. The application period ends on April 19. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
Registration to attend the presentation, lunch and optional tours will remain open until May 1.
NOTE: All companies accepted for a one-on-one meeting will be notified of acceptance by Prescience International by April 24 and emailed a specific link to pay the required registration fees online.
JJIC & JJDC Biographies
Jeff Calcagno, M.D. | Principal, Venture Investments, Johnson & Johnson Development Corporation
Jeff Calcagno, Principal, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2013. He is based in Silicon Valley, California. Dr. Calcagno came to J&J in 2011 and held roles in the Corporate Office of Science & Technology and the California Innovation Center. He has over two decades of healthcare and business experience: as a clinician, management consultant, research analyst, entrepreneur, and venture investor. Dr. Calcagno began his business career as a management consultant at McKinsey & Company. He later served as a healthcare research analyst at JP Morgan Hambrecht & Quist. As an entrepreneur, he ran corporate development and operations for WIDCOMM, a technology company acquired by Broadcom, and served as CFO & CBO for Vela Pharmaceuticals, a venture-backed drug development company. From 2006 to 2010 he was a Principal & Kauffman Fellow at Scale Venture Partners, a venture fund with over $1B under management. Dr. Calcagno graduated Phi Beta Kappa in Biology from Harvard College and earned an MD from Harvard Medical School, where he was a Rotary International Ambassadorial Scholar. He completed his medical-psychiatric internship and psychiatry residency at UCLA’s Neuropsychiatric Institute, served as program chief resident, and was awarded and completed a clinical neuropharmacology fellowship.
Adam Keeney, Ph.D. | Vice President, Head of Transactions, Johnson & Jonson Innovation Center California
Adam Keeney heads the Transactions group within the Johnson & Jonson Innovation Center - a novel approach to accelerate early innovation and enhance opportunities for collaboration and investment across J&J's healthcare businesses. Located in Menlo Park, CA, the West Coast Innovation Center will serve as a regional hub focused on identifying early-stage innovations, establishing novel collaborations and enhancing speed of development. The innovation center houses science and technology experts as well as local deal-making capabilities, with flexibility to adapt deal structures to match early-stage opportunities (defined as before clinical proof of concept). Dr. Keeney has a PhD in Neuropharmacology from the University of Nottingham, UK. After his post doc studies, Dr. Keeney joined H. Lundbeck A/S in Copenhagen (Denmark) working in the Neuroscience Drug Discovery group. While at Lundbeck, Dr. Keeney moved to lead the Scientific Licensing team within Business Development. Dr. Keeney joined the J&J Pharmaceutical Business Development group in 2004 and has held numerous roles with increasing responsibility, most recently as Vice President and Head of Cardiovascular & Metabolism Licensing.
Asish K. Xavier, Ph.D. | Vice President, Venture Investments, Johnson & Johnson Development Corporation
Asish Xavier, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2004. He is based in Silicon Valley, California. Dr. Xavier previously worked in business development at BioRexis Pharmaceutical, Inc., which was acquired by Pfizer in 2007. While at BioRexis, he assisted the company in raising a $30 million second round of financing. Dr. Xavier has worked in business development at Structural GenomiX, Inc., acquired by Eli Lilly in 2008, and was a project leader at Message Pharmaceuticals, Inc. Dr. Xavier received a PhD from the University of Houston and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he graduated with honors. He received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. Dr. Xavier was also a postdoctoral research Fellow in the Department of Chemistry at Johns Hopkins University.